Gabapentin enacarbil - Arbor Pharmaceuticals
Alternative Names: 1838262; ASP8825; Gabapentin-XP; GSK 1838262; Horizant; Regnite; Solzira; XP13512Latest Information Update: 05 Nov 2023
At a glance
- Originator XenoPort
- Developer Arbor Pharmaceuticals; Astellas Pharma; GlaxoSmithKline; National Institute on Alcohol Abuse and Alcoholism; XenoPort
- Class Acetic acids; Antiepileptic drugs; Carbamates; Cyclohexanecarboxylic acids; Gabapentinoids; Small molecules
- Mechanism of Action CACNA2D1 protein modulators; GABA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Restless legs syndrome
Highest Development Phases
- Marketed Postherpetic neuralgia; Restless legs syndrome
- Discontinued Alcoholism; Diabetic neuropathies; Migraine